More than three dozen cases of women experiencing miscarriages or stillbirths after receiving the COVID-19 vaccine have been reported to the Vaccine Adverse Event Reporting System. It’s estimated that less than 1% of vaccine reactions are reported on VAERS.

The FDA, nor Pfizer or Moderna have commented on the cases filed with VAERS. The CDC has said that pregnant or nursing women who are part of groups recommended to get the vaccine, such as health care workers, can choose to get vaccinated.

And a 32-year-old woman in Virginia who was eight weeks pregnant reported having a miscarriage five days after being injected with the first dose of a Moderna vaccine in January. She had consulted with two obstetrics and gynecologists (OB-GYN) prior to receiving the vaccine on Jan. 14. She experienced abdominal cramping and vaginal bleeding two days later and had a miscarriage on Jan. 19. She had only been taking prenatal vitamins.

3 Dozen Cases of Spontaneous Miscarriages, Stillbirths Occurring After CV Injection

The World Health Organization does not recommend vaccination of pregnant women due to “insufficient data”. Pregnant women were excluded from trials originally, but Pfizer is currently conducting trials on 4,000 pregnant women in their second and third trimesters.

Related: How To Detoxify and Heal From Vaccinations – For Adults and Children

Many people have died shortly after receiving the first dose of the Covid-19 vaccine.

In Norway, 29 people over the age of 75 have passed away after receiving the vaccine. Most of those who passed, also experienced severe side effects from the vaccine like nausea and vomiting, fever, and reactions at the injection site.

Norway has since suggested that the vaccine may be too risky for those who are very old and terminally ill.

Pfizer and BioNTech are working with the Norwegian regulator to investigate the deaths in Norway, Pfizer said in an e-mailed statement. The agency found that ‘the number of incidents so far is not alarming, and in line with expectations,‘ Pfizer said.

55 Americans Have Died Following mRNA COVID Injections as Norway Death Toll Rises To 29

Additionally, 55 Americans have died since receiving the first dose of the vaccine. Another 10 people have died in Germany after receiving the vaccine. People have died anywhere from one to four days after receiving the vaccine.

In addition to the sudden deaths after the vaccine, there have been a high number of adverse reactions.

Related: How To Detoxify and Heal From Vaccinations – For Adults and Children

In the following video, Good Morning America’s anchor attempts to put these adverse reactions into perspective:

Earlier this month Dr. Anthony Fauci said it was likely that some businesses and institutions will require employees to be vaccinated. He also said it’s “quite possible” the vaccine will be required for international travel.

While Dr. Fauci does not believe a national vaccine mandate will be put in place, he does think it’s possible that local level mandates will be put in place.

There are already many vaccines required at state or local levels. The Covid-19 vaccine is still an experimental vaccine that has only been authorized for emergency use. Moderna and Pfizer have not finished stage three clinical trials for the vaccines.

According to news reports, about half of all front-line workers in Riverside County, California, have refused the vaccine, as have 60% of nursing home staff in Ohio, 40% of staff at Chicago’s Loretto Hospital and 40% of LA’s front-line workers. Similar rates of vaccine refusal are being reported in several European countries.

Fauci Now Says COVID-19 Vaccine May Become Mandatory

As of late December, the risk of adverse reactions for the vaccine was 2.79%, compared to the mortality rate of covid-19, which is around 0.26% for noninstitutionalized individuals, and an even smaller rate of mortality under the age of 40, 0.01%.

Related: How To Detoxify and Heal From Vaccinations – For Adults and Children

The Food and Drug Administration (FDA) has released updated safety guidelines for coronavirus vaccine makers that would make it impossible for a vaccine to be ready by election day. The FDA now says that vaccine manufacturers need to follow vaccine trial participants for two months to monitor side effects before seeking emergency approval.

Data from Phase 3 studies should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine’s benefit-risk profile, including: adverse events; cases of severe COVID-19 disease among study subjects; and cases of COVID-19 occurring during the timeframe when adaptive (rather than innate) and memory immune responses to the vaccine would be responsible for a protective effect.

Emergency Use Authorization for Vaccines to Prevent COVID-19

President Trump has continued to insist that a vaccine will be ready before elections on November 3rd, and the administration had tried to block the FDA from formally publishing these safety guidelines. The FDA has been communicating these guidelines to the public and vaccine manufacturers informally.

Related: Coronavirus Supplement Review

Seven former FDA commissioners released an op-ed in the Washington Post that criticized President Trump’s handling of the COVID-19 vaccine process.

But a safe and effective vaccine will not be enough; people will also have to choose to take it. This depends on widespread confidence that the vaccine approval was based on sound science and not politics. If the White House takes the unprecedented step of trying to tip the scales on how safety and benefits will be judged, the impact on public trust will render an effective vaccine much less so.”

7 former FDA commissioners: The Trump administration is undermining the credibility of the FDA

Related: How To Detoxify and Heal From Vaccinations – For Adults and Children

Two of the commissioners responsible for this statement, Scott Gottlieb and Mark McClellan, are on the boards of two of the companies with a coronavirus vaccine in development, Pfizer and Johnson & Johnson respectively.

The secretary of California Health and Human Services, Dr. Mark Ghaly, announced on Friday that the state of California will be forming an independent review board to evaluate COVID-19 vaccine data.

We think it is an appropriate approach to take, especially because things are moving so quickly. We want to make sure — despite the urge and interest in having a useful vaccine — that we do it with the utmost safety of Californians in mind.”

Dr. Mark Ghaly, secretary of CA Health and Human Services

Related: Natural Coronavirus Prevention

California is not the only state or jurisdiction saying they will independently analyze coronavirus vaccines. Others include Colorado, the District of Columbia, Michigan, New York, Oregon, and West Virginia. Montana and Wyoming have said they would only administer vaccines if they had completed clinical trials and had been reviewed by an outside committee.

Confidence in the coronavirus vaccine has been steadily waning as government timelines continue to waver. President Trump has consistently promised that the vaccine will be ready before the election and all Americans will be vaccinated by April, while the director of the CDC, Dr. Robert Redfield, maintains that widespread vaccination will not be achieved until the third quarter of 2021. According to a new survey from the Pew Research Center, only 51% of Americans would probably get the vaccine as opposed to the 72% that would give the same answer in May.

The drama surrounding COVID-19 vaccines continues as President Trump suggested that the executive branch would not support stricter guidelines for evaluating a COVID-19 vaccine. If approved, the new guidelines from the Food and Drug Administration (FDA) would include additional specifications for clinical trial data and a committee of independent experts to review that data before any vaccine is approved. President Trump continues to promise a vaccine before the end of the year, despite experts saying that is unlikely. Trump asserted that the plan to introduce more guidelines was political in nature.

Related: Natural Coronavirus Prevention

That has to be approved by the White House. We may or may not approve it. That sounds like a political move. I think that was a political move more than anything else…”

President Trump

This announcement will add fuel to the growing anti-Trump-vaxxer movement taking place in the Democratic party. Vice presidential nominee Kamala Harris cast doubt on the efficacy and safety of a COVID-19 vaccine implemented during a Trump presidency earlier in September.

I will say that I would not trust Donald Trump, and it would have to be a credible source of information that talks about the efficacy and the reliability of whatever he’s talking about….I will not take his word for it.”

Senator Kamala Harris

Related: How To Detoxify and Heal From Vaccinations – For Adults and Children

Scientists may have to change the way they conduct COVID-19 studies, as the United States is facing a monkey shortage. Non-human primates are usually the last step before products go into human trials, but with over 100 new COVID-19 vaccines, therapies, and drugs in development, there aren’t enough monkeys to go around.

The reasons for the shortage are threefold. First, COVID-19 has created extraordinary demand for monkeys. Second, this coincided with a massive drop in supply from China, which provided 60 percent of the nearly 35,000 monkeys imported to the U.S. last year and which shut off exports after COVID-19 hit. And third, these pandemic-related events are exacerbating preexisting monkey shortfalls. A 2018 National Institutes of Health report had found that NIH-funded national primate centers would be unable to meet future demand and specifically discussed a “strategic monkey reserve” to provide “surge capability for unpredictable disease outbreaks.” A disease outbreak is upon us; the strategic monkey reserve was never created.”

The Atlantic

Related: Coronavirus Supplement Review

Monkeys infected with COVID-19 are also required to be put in special labs, called Animal Biosafety Level 3 labs. There are a limited number of these labs in the United States.

Recommended: How to Eliminate IBS, IBD, Leaky Gut 

In an attempt to manage the monkey demand, the National Institutes of Health (NIH) has formed a public-private initiative, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), designed to control which products and which companies get to use the limited supply of testing monkeys. This initiative has the potential to save time and move scientists closer to vaccines, treatments, and therapies for COVID-19, but it could also make it difficult for those who aren’t affiliated with the project to gain access to non-human primate trials. A quick look at the leadership organizations involved in ACTIV show names like Merck, Johnson & Johson, Sanofi, AstraZeneca, GlaxoSmithKline, and the Bill and Melinda Gates Foundation. In light of that, the decision to control access to the final stages of animal testing feels less like an efficiency or safety measure, and more like a way for those who already have the power to keep it.